---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120278"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:50:59.761832+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q3 revenue $0.6M, net loss $16.4M; PBGENE-HBV enters clinic

## Summary
- Revenue $0.6M down from $13.1M YoY; net loss $16.4M ($2.25/share) vs $8.1M loss in Q3 2023.
- Cash $121.3M sufficient into H2 2026, supplemented by $22.5M loan from Banc of California (maturing June 2027).
- PBGENE-HBV CTA approved in Moldova; patient screening underway; Phase 1 data expected in 2025.
- PBGENE-3243 (mitochondrial disease) IND/CTA expected in 2025; regained rights to three Prevail programs under assessment.
- Appointed Dr. Murray Abramson SVP Head of Clinical Development and John Fry as Strategic Clinical Advisor for hepatitis.

## SEC filing metadata
- accession: 0000950170-24-120278
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017024120278/0000950170-24-120278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017024120278/dtil-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120278
- JSON: https://secwatch.observer/filing/0000950170-24-120278.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.